Welcome to our dedicated page for Positron news (Ticker: POSC), a resource for investors and traders seeking the latest updates and insights on Positron stock.
Positron Corporation develops and commercializes PET and PET-CT molecular imaging systems and related clinical services for nuclear medicine providers in North America. The company specializes in cardiac Positron Emission Tomography applications, including PET-CT scanners and practice support for cardiovascular diagnostic providers.
Company news commonly covers scanner sales and multi-unit orders, long-term service agreements, the NeuSight PET-CT 64-slice system, industry partnerships, product development, regulatory activities, capital raises, and its transition to SEC reporting status. Updates also describe how Positron combines imaging hardware, software, clinical support, technical support, and training services for nuclear cardiology and broader molecular imaging practices.
Positron Corporation (OTC: POSC) announces a collaboration with Dr. Robert Bober and Ochsner Health for a clinical study of its new Affinity PET-CT 4D imaging device. This FDA-compliant study, commencing mid-January 2023, aims to evaluate the device's image quality and performance in cardiac PET imaging. Dr. Bober's leadership is pivotal for gathering empirical data essential for marketing the system. Following completion and FDA 510k certification, Positron intends to commercialize the device in Q1 2023, targeting nuclear cardiology and oncology markets.
Positron Corporation (OTC: POSC) has announced the purchase of its first Affinity PET-CT system from Neusoft Medical Systems, which is currently in transit to the U.S. for validation. This marks a crucial step in launching the device, aimed at cardiac and oncology imaging. The company plans to reveal details about participating hospitals and expects to submit a 510K application to the FDA soon. President Adel Abdullah highlighted the excitement among industry partners for the upcoming validation studies, set to begin in September and conclude by November 2022.
Positron Corporation (OTC: POSC) announced the appointment of Christopher Reilly to lead its PET-CT Services and Systems Sales. With over 30 years of experience in SPECT imaging, Reilly aims to facilitate the transition from SPECT to PET imaging for hospitals and cardiology practices. The company will validate its new PET-CT device in collaboration with a leading healthcare organization over the next three months. President Adel Abdullah expressed confidence in Reilly's expertise, which is expected to support Positron's sales and marketing initiatives as it prepares to launch its new product.
Positron Corporation (OTC: POSC) announced its partnership with Medical Device Academy (MDA) to assist in the 510K submission for its new PET/CT device to the FDA. The company aims to file the application within 60 days, seeking approval within 100 days of filing. President Adel Abdullah highlighted MDA's expertise as crucial for the application process. This advancement is part of Positron's strategy to enhance cardiac and oncology diagnostics, positioning its innovative PET technology to meet market demand.
Positron Corporation (OTC: POSC) has announced a collaboration with Neusoft Medical Systems to develop a new PET/CT imaging system, marking a significant expansion into the oncology market. The company plans to submit a 510K application to the FDA soon. With an expected market size of $3.34 billion by 2028, Positron aims for a 10% market share. The new system promises superior imaging capabilities, thus enhancing diagnostic accuracy in nuclear cardiology and oncology. Positron emphasizes growth through transparency and is focused on expanding its marketing and sales efforts in the healthcare sector.
Positron Corporation (OTC: POSC) announced a strategic partnership with Neusoft Medical Systems to develop and distribute a new PET/CT nuclear imaging device. This collaboration aims to enhance Positron's technology for nuclear cardiology and expand into oncology diagnostics. They plan to submit a 510K application to the FDA for device certification. Positron has ordered its new PET/CT systems for validation testing and purchased existing equipment to support installations in 2022. The U.S. market remains the primary focus, with future expansion plans into Canada and Mexico.
Positron Corp (OTC: POSC) has achieved 'Pink Current' status with OTC Pink Markets, enhancing transparency regarding its financial health. This status eliminates the 'stop or yield' sign for non-filing companies, allowing for improved credibility. President Adel Abdullah expressed gratitude for shareholder support, emphasizing that this accomplishment is vital for increasing shareholder value and concentrating on revenue growth in cardiac PET imaging. The company aims to upgrade to OTCQB as soon as it meets all trading requirements.
Positron Corp (OTC: POSC) has secured full OTCIQ access for its filing process with OTC Markets, aiming to become current with OTC Pink Markets, which will remove the 'stop' sign on its ticker. This update should mitigate the impact of SEC Rule 15c2-11 changes on POSC shares. The company has engaged Rosenberg Rich Baker Berman, P.A. for auditing, essential for its SEC Form 10 filing. Positron plans to eventually upgrade to OTCQB or OTCQX, or up-list to Nasdaq, with updates expected by the end of Q3.
Positron Corporation (OTC: POSC) has engaged I-Square Ventures to enhance its value proposition and market strategy in nuclear medicine. I-Square has a strong track record in driving growth for healthcare and technology sectors. Positron's President, Adel Abdullah, highlighted the critical nature of this collaboration amid a favorable PET technology market. Dr. Chiranjeev Bordoloi of I-Square noted Positron's unique position to capture market share as the industry shifts from SPECT to PET systems, thanks to innovations that lower PET costs and enhance diagnostic accuracy.
Positron Corp (OTC: POSC) announced the engagement of Skyline Corporate Communications Group, LLC for investor relations and corporate communications. The partnership aims to enhance communication of Positron's growth objectives and operating activities within the financial community. Skyline will provide strategic messaging guidance as Positron enters an expansion phase. Positron specializes in cardiac Positron Emission Tomography (PET) imaging, offering advanced diagnostic solutions to improve patient outcomes and support cost-effective healthcare.